Jamal Tarazi - Publications, H-index & Citations

Back

Jamal Tarazi

pfizer

27H-index

100Paper Count

5.3KCitation Count

Published Papers 26

Publication Date

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

Journal of Urology

IF6.8

2026-05-01

PREAI

Shore, Neal D.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gomez Caamano, Antonio; Saranchuk, Jeff W.; Nordquist, Luke T.; Ferreira, Ubirajara; Tang, Yiyun; Rosbrook, Brad; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Tarazi, Jamal; Freedland, Stephen J.

Save

PROSTATE-SPECIFIC ANTIGEN DYNAMICS FROM THE PHASE 3 EMBARK TRIAL: A POST HOC ANALYSIS

JOURNAL OF UROLOGY

IF6.8

2024-05-01

PREAI

Freedland, Stephen J.; De Giorgi, Ugo; Gleave, Martin; Tarazi, Jamal; Tang, Yiyun; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Shore, Neal D.

Save

CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

FUTURE ONCOLOGY

IF2.6

2024-01-08

OAAI

Steinberg, Gary D.; Shore, Neal D.; Redorta, Joan Palou; Galsky, Matthew D.; Bedke, Jens; Ku, Ja Hyeon; Kretkowski, Michal; Hu, Hailong; Penkov, Konstantin; Vermette, Jennifer J.; Tarazi, Jamal C.; Randall, Alison E.; Pierce, Kristen J.; Saltzstein, Daniel; Powles, Thomas B.

Save

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2023-10-19

PREAI

Freedland, Stephen J.; Luz, Murilo de Almeida; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey T.; Pieczonka, Christopher M.; Haas, Gabriel P.; Kim, Choung-Soo; Ramirez-Backhaus, Miguel; Rannikko, Antti; Tarazi, Jamal; Sridharan, Swetha; Sugg, Jennifer; Tang, Yiyun; Tutrone, Ronald F.; Venugopal, Balaji; Villers, Arnauld; Woo, Henry H.; Zohren, Fabian; Shore, Neal D.

Save

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

EUROPEAN JOURNAL OF CANCER

IF7.1

2021-03-01

OAAI

Atkins, Michael B.; Plimack, Elizabeth R.; Puzanov, Igor; Fishman, Mayer N.; McDermott, David F.; Cho, Daniel C.; Vaishampayan, Ulka; George, Saby; Tarazi, Jamal C.; Duggan, William; Perini, Rodolfo; Thakur, Mahgull; Fernandez, Kathrine C.; Choueiri, Toni K.

Save

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma

FUTURE ONCOLOGY

IF2.6

2020-05-04

OAAI

Murphy, Danielle A.; Rini, Brian I.; Escudier, Bernard; Motzer, Robert J.; Wang, Panpan; Li, Sherry; Williams, J. Andrew; Tarazi, Jamal C.; Martini, Jean-Francois

Save

Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers

CANCER RESEARCH

IF16.6

2019-07-01

PREAI

Atkins, Michael; Martini, Jean-Francois; Plimack, Elizabeth; McDermott, David; Puzanov, Igor; Fishman, Mayer; Cho, Daniel; Vaishampayan, Ulka; Rosbrook, Brad; Fernandez, Kathrine; Tarazi, Jamal; George, Saby; Choueiri, Toni

Save

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma

TARGETED ONCOLOGY

IF4

2017-03-30

PREAI

Rini, Brian I.; Gruenwald, Victor; Jonasch, Eric; Fishman, Mayer N.; Tomita, Yoshihiko; Michaelson, M. Dror; Tarazi, Jamal; Cisar, Laura; Hariharan, Subramanian; Bair, Angel H.; Rosbrook, Brad; Hutson, Thomas E.

Save

Long-term duration of axitinib treatment in advanced renal cell carcinoma

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Rini, B. I.; Gruenwald, V.; Jonasch, E.; Fishman, M. N.; Tomita, Y.; Michaelson, M. D.; Tarazi, J.; Cisar, L.; Blair, A. H.; Rosbrook, B.; Hutson, T.

Save

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Vizcarrondo, F. R.; Patel, S. P.; Pennell, N. A.; Pakkala, S.; West, H.; Kratzke, R.; Tarazi, J.; Wilner, K.; Polli, A.; Tan, W.; Liu, Y.; Valota, O.; Piperdi, B.; Reckamp, K. L.

Save

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

TARGETED ONCOLOGY

IF4

2015-09-24

OAAI

Chen, Ying; Rini, Brian I.; Motzer, Robert J.; Dutcher, Janice P.; Rixe, Olivier; Wilding, George; Stadler, Walter M.; Tarazi, Jamal; Garrett, May; Pithavala, Yazdi K.

Save

Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

EUROPEAN JOURNAL OF CANCER

IF7.1

2014-11-01

PREAI

Williams, J. A.; Martini, J. F.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Tarazi, J.; Li, S.; English, P. A.

Save

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

BRITISH JOURNAL OF CANCER

IF6.8

2014-05-13

OAAI

Escudier, B.; Michaelson, M. D.; Motzer, R. J.; Hutson, T. E.; Clark, J. I.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Staehler, M.; Tarazi, J.; Rosbrook, B.; Cisar, L.; Hariharan, S.; Kim, S.; Rini, B. I.

Save

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

TARGETED ONCOLOGY

IF4

2014-03-05

OAAI

Rini, Brian I.; Quinn, David I.; Baum, Michael; Wood, Laura S.; Tarazi, Jamal; Rosbrook, Brad; Arruda, Lillian Shahied; Cisar, Laura; Roberts, W. Gregory; Kim, Sinil; Motzer, Robert J.

Save

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

BRITISH JOURNAL OF CANCER

IF6.8

2014-01-14

OAAI

Hoh, C. K.; Burris, H. A., III; Bendell, J. C.; Tarazi, J.; Rosbrook, B.; Kim, S.; Infante, J. R.; Reid, T. R.

Save

Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study

CLINICAL COLORECTAL CANCER

IF3.2

2013-12-01

PREAI

Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carlo; Wainberg, Zev A.; Kim, Jong Gwang; Pericay, Carles; Pastorelli, Davide; Tarazi, Jamal; Rosbrook, Brad; Bloom, Joanna; Ricart, Alejandro D.; Kim, Sinil; Sobrero, Alberto F.

Save

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

CANCER

IF5.1

2013-04-19

OAAI

Infante, Jeffrey R.; Reid, Tony R.; Cohn, Allen L.; Edenfield, William J.; Cescon, Terrence P.; Hamm, John T.; Malik, Imtiaz A.; Rado, Thomas A.; McGee, Philip J.; Richards, Donald A.; Tarazi, Jamal; Rosbrook, Brad; Kim, Sinil; Cartwright, Thomas H.

Save

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

BRITISH JOURNAL OF CANCER

IF6.8

2013-04-11

OAAI

Cella, D.; Escudier, B.; Rini, B.; Chen, C.; Bhattacharyya, H.; Tarazi, J.; Rosbrook, B.; Kim, S.; Motzer, R.

Save

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

BRITISH JOURNAL OF CANCER

IF6.8

2012-09-20

OAAI

Martin, L. P.; Kozloff, M. F.; Herbst, R. S.; Samuel, T. A.; Kim, S.; Rosbrook, B.; Tortorici, M.; Chen, Y.; Tarazi, J.; Olszanski, A. J.; Rado, T.; Starr, A.; Cohen, R. B.

Save

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

BRITISH JOURNAL OF CANCER

IF6.8

2012-09-18

OAAI

Kozloff, M. F.; Martin, L. P.; Krzakowski, M.; Samuel, T. A.; Rado, T. A.; Arriola, E.; De Castro Carpeno, J.; Herbst, R. S.; Tarazi, J.; Kim, S.; Rosbrook, B.; Tortorici, M.; Olszanski, A. J.; Cohen, R. B.

Save

Research Directions